GAITHERSBURG, Md., Oct. 8, 2024
/PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB)
("LakeShore Biopharma" or the "Company"), a global
biopharmaceutical company dedicated to discovering, developing,
manufacturing, and delivering new generations of vaccines and
therapeutic biologics for infectious diseases and cancer, today
announced that it is providing financial guidance for the half year
of its fiscal year of 2025 and reaffirming its financial guidance
for the full year of its fiscal year 2025 ending on March 31, 2025 ("Fiscal Year 2025"), underlining
the Company's strong execution and positive business momentum.
LakeShore Biopharma's previously issued guidance anticipated
double-digit year-over-year revenue growth during Fiscal Year 2025
and noted that the Company expected to achieve breakeven during the
period. The Company's performance in the first six months of its
Fiscal Year 2025 has demonstrated solid progress towards these
goals, with a preliminary total revenue estimate for the first six
months in the range of RMB350 million
to RMB380 million, representing
substantial growth of 28% to 39% from RMB273.1 million in revenues during the same
period in its fiscal year 2024.
In addition to advancing its existing pipeline, LakeShore
Biopharma has been vigorously pursuing strategic initiatives
including cost reductions, organizational restructuring and
optimization, and management process enhancements to boost
operational efficiency and eliminate non-essential expenditures.
Furthermore, the Company is also committed to driving future growth
through strategic alliances, including product licensing, asset
purchase agreements, partnerships, and co-promotion deals with more
diversified pipeline products.
Mr. Xu Wang, Chief Executive
Officer of the Company, commented, "By reaffirming our full-year
guidance, we are expressing belief in our ability to maintain our
positive momentum and achieve our financial and operational
objectives. With our new management team in place, Lakeshore
Biopharma has not only maintained smooth operations, but also
secured second position in China's
Rabies vaccine market. Armed with a robust business model and a
strong pipeline, we have consistently demonstrated our capacity to
execute our core strategies effectively. Building on this solid
foundation, we are actively forging long-term strategic
partnerships through licensing, promotions, and other collaborative
agreements. As we progress through Fiscal Year 2025 with a clear
plan to enhance sustainability, efficiency, and innovation, I am
confident that our team will deliver success across these areas,
creating enduring value for our company and our shareholders."
About LakeShore Biopharma
LakeShore Biopharma,
previously known as YS Biopharma, is a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and
delivering new generations of vaccines and therapeutic biologics
for infectious diseases and cancer. It has developed a proprietary
PIKA® immunomodulating technology platform and a new
generation of preventive and therapeutic biologics targeting
Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other
virus infections. The Company operates in China, the United
States, Singapore, and
the Philippines, and is led by a
management team that combines rich local expertise and global
experience in the biopharmaceutical industry. For more information,
please visit investor.lakeshorebio.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, Section 21E of the Securities Exchange Act of
1934, as amended, and the Private Securities Litigation Reform Act
of 1995. All statements other than statements of historical or
current fact included in this press release are forward-looking
statements, including but not limited to statements regarding the
expected growth of LakeShore Biopharma, the development progress of
all product candidates, the progress and results of all clinical
trials, LakeShore Biopharma's ability to source and retain talent,
and the cash position of LakeShore Biopharma. Forward-looking
statements may be identified by the use of words such as
"estimate," "plan," "project," "potential," "forecast," "intend,"
"will," "expect," "anticipate," "believe," "goal," "seek," "target"
or other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. These
statements are based on various assumptions, whether identified in
this press release, and on the current expectations of LakeShore
Biopharma's management and are not predictions of actual
performance.
LakeShore Biopharma cannot assure you the forward-looking
statements in this press release will be accurate. These
forward-looking statements are subject to a number of risks and
uncertainties, including those included under the heading "Risk
Factors" in the Company's Annual Report on Form 20-F filed with the
Securities and Exchange Commission (the "SEC"), and other risks
described in documents subsequently filed or furnished by the
Company from time to time with the SEC. There may be additional
risks that LakeShore Biopharma does not presently know or that
LakeShore Biopharma currently believes are immaterial that could
also cause actual results to differ from those contained in the
forward-looking statements. In light of the significant
uncertainties in these forward-looking statements, nothing in this
press release should be regarded as a representation by any person
that the forward-looking statements set forth herein will be
achieved or that any of the contemplated results of such
forward-looking statements will be achieved. The forward-looking
statements in this press release represent the views of LakeShore
Biopharma as of the date of this press release. Subsequent events
and developments may cause those views to change. However, while
LakeShore Biopharma may update these forward-looking statements in
the future, there is no current intention to do so, except to the
extent required by applicable law. You should, therefore, not rely
on these forward-looking statements as representing the views of
LakeShore Biopharma as of any date subsequent to the date of this
press release. Except as may be required by law, LakeShore
Biopharma does not undertake any duty to update these
forward-looking statements.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com
View original
content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-provides-fiscal-half-year-2025-financial-guidance-and-reaffirms-fiscal-year-2025-financial-guidance-302270029.html
SOURCE LakeShore Biopharma Co., Ltd.